Tag: M.W=350-400

Cheng, Jing published the artcileInfluence of lactitol and psyllium on bowel function in constipated Indian volunteers: a randomized, controlled trial, COA of Formula: C17H18N3NaO3S, the publication is Nutrients (2019), 11(5), 1130, database is CAplus and MEDLINE.

Psyllium and lactitol have been reported to increase fecal volume, moisture content and bowel movement frequency (BMF). However, the benefits of their combined use on constipation has not been examined The aim of this study was to evaluate the effects of a 4-wk intervention with lactitol and/or psyllium on bowel function in constipated volunteers. Adults (N = 172) who were diagnosed with functional constipation per Rome III criteria were randomized to four treatment groups: 10 g lactitol, 3.5 g psyllium, a combination of 10 g lactitol and 3.5 g psyllium, or placebo. The primary endpoint was change in BMF from Day 0 to 28 as compared to placebo. Secondary endpoints were assessed by inventories, including stool consistency, patient assessment of constipation symptoms and quality of life, relief of constipation, 24-h food recall, phys. activity, product satisfaction and adverse events (AE). BMF increased by 3.0 BMs with lactitol, by 2.9 with psyllium, and by 3.1 with the combination, but was not different from placebo (3.7 BMs). Other clin. endpoints were similar between treatments. No serious AEs were reported. In conclusion, this study showed a similar effect on relief of constipation in all treatment groups. The treatments that were administered to the volunteers were well tolerated.

Nutrients published new progress about 161796-78-7. 161796-78-7 belongs to imidazoles-derivatives, auxiliary class Membrane Transporter/Ion Channel,Proton Pump, name is Sodium (S)-6-methoxy-2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide, and the molecular formula is C17H18N3NaO3S, COA of Formula: C17H18N3NaO3S.

Referemce:
https://en.wikipedia.org/wiki/Imidazole,
Imidazole | C3H4N2 – PubChem

Housman, Seth T. published the artcilePhysical compatibility of telavancin hydrochloride with select i.v. drugs during simulated Y-site administration, Related Products of imidazoles-derivatives, the publication is American Journal of Health-System Pharmacy (2011), 68(23), 2265-2270, database is CAplus and MEDLINE.

The phys. compatibility of telavancin with select i.v. drugs during simulated Y-site administration was evaluated. Telavancin for injection was reconstituted according to manufacturer’s recommendations and diluted with 0.9% sodium chloride injection, 5% dextrose injection, or lactated Ringer’s injection to a concentration of 7.5 mg/mL. A Y site was simulated in culture tubes by mixing 5 mL of telavancin solution with 5 mL of a tested drug solution and then switching the order of drug mixing. All mixtures were prepared in duplicate and stored at room temperature Solutions were inspected for visual, turbidity, and pH changes immediately after preparation and 15, 60, and 120 min after preparation Of the 52 drugs tested, telavancin was phys. compatible with 39 drugs in all test solutions Telavancin was incompatible with amphotericin B deoxycholate, liposomal amphotericin B, digoxin, esomeprazole sodium, furosemide, levofloxacin, and micafungin sodium in all diluents. Colistimethate sodium, cyclosporine, heparin sodium, imipenem-cilastatin sodium, methylprednisolone sodium succinate, and propofol were incompatible with telavancin in specific diluents. Incompatibilities included precipitation, pos. Tyndall beam test, and increases in turbidity. There were no substantial changes in pH over the 120-min study period. Telavancin 7.5 mg/mL in 0.9% sodium chloride injection, 5% dextrose injection, and lactated Ringer’s injection was found to be phys. compatible for 120 min at room temperature with 39 of the 52 drugs tested during simulated Y-site administration. Seven drugs were incompatible in all diluents, and 6 were incompatible in at least one diluent.

American Journal of Health-System Pharmacy published new progress about 161796-78-7. 161796-78-7 belongs to imidazoles-derivatives, auxiliary class Membrane Transporter/Ion Channel,Proton Pump, name is Sodium (S)-6-methoxy-2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide, and the molecular formula is C17H18N3NaO3S, Related Products of imidazoles-derivatives.

Referemce:
https://en.wikipedia.org/wiki/Imidazole,
Imidazole | C3H4N2 – PubChem

Hu, Xiao published the artcileDetermination of S-omeprazole sodium and the related substances by RP-HPLC, Product Details of C17H18N3NaO3S, the publication is Zhongguo Yaofang (2009), 20(22), 1744-1746, database is CAplus.

The aim of this paper is to establish an RP-HPLC method for content determination of S-omeprazole sodium and its related substances. The separation of S-omeprazole sodium and the related substances was carried out on a Phenomenex Luna C₁V8 column, and the mobile phase consisted of methanol-0.033 mol/L^-1 ammonium dihydrogen phosphate-triethylamine. The detection wavelength was 302 nm, the flow rate was 1.0 mL/min^-1, the column temperature was 25°, and the sample size was 20 μL. The linear range of omeprazole sodium was 10-500 mg/L^-1 (r = 0.9997). The average recovery rate was 100.27% (RSD = 0.74%). The average content of the related substances in samples was 0.42%. This method is simple, accurate, specific, and applicable for content determination of S-omeprazole sodium and its related substances.

Zhongguo Yaofang published new progress about 161796-78-7. 161796-78-7 belongs to imidazoles-derivatives, auxiliary class Membrane Transporter/Ion Channel,Proton Pump, name is Sodium (S)-6-methoxy-2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide, and the molecular formula is C17H18N3NaO3S, Product Details of C17H18N3NaO3S.

Referemce:
https://en.wikipedia.org/wiki/Imidazole,
Imidazole | C3H4N2 – PubChem

Kumar, Y. Naveen published the artcileFormulation development of controlled release formulation of esomeprazole sodium tablets, HPLC of Formula: 161796-78-7, the publication is Indo American Journal of Pharmaceutical Sciences (2015), 2(5), 955-960, database is CAplus.

The main aim of this work is Esomeprazole sodium is formulated as controlled release tablets to provide desired effect at certain time in maintained drug concentration without any unwanted effect with patient compliance also to improve it bioavailability by decreasing its expose to gastric acid. A controlled release dosage form is designed to release the drug from the dosage form at a time other than promptly after administration. UV Spectrophotometric method has been developed for the estimation of Esomeprazole in pharmaceutical formulations. Then the tablets were prepared by dry granulation method rather than direct compression because of cohesive property of the drug. Optimized core tablet then subjected for enteric coating by selected base coat polymer cellulose derivative for preventing core tablet from moisture. The coated formulations were compared with marketed sample (ESOZ) for optimization. Dissolution results of tablets with enteric coating have shown release of Esomeprazole in simulated gastrointestinal fluid pH 1.2, but most of the drug released in pH 6.8 Phosphate buffer. At the end it was found that prepared formulation gave satisfactory results compared with marketed sample dissolution profile. Hence prepared formulation bypass the degradation of Esomeprazole by enteric coating approach and can be used as single unit dosage for the treatment of acid-related diseases. Thus a pharmaceutically equivalent, robust formulation of Esomeprazole controlled release tablet was developed.

Indo American Journal of Pharmaceutical Sciences published new progress about 161796-78-7. 161796-78-7 belongs to imidazoles-derivatives, auxiliary class Membrane Transporter/Ion Channel,Proton Pump, name is Sodium (S)-6-methoxy-2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide, and the molecular formula is C17H18N3NaO3S, HPLC of Formula: 161796-78-7.

Referemce:
https://en.wikipedia.org/wiki/Imidazole,
Imidazole | C3H4N2 – PubChem

Subbaiah, B. Venkata published the artcilePREPARATIVE ISOLATION AND UPLC-TOF MS IDENTIFICATION OF EIGHT DEGRADANTS FROM STRESSED TABLETS OF ESOMEPRAZOLE, Application In Synthesis of 161796-78-7, the publication is Journal of Liquid Chromatography & Related Technologies (2013), 36(9), 1243-1250, database is CAplus.

Esomeprazole is a proton pump inhibitor, used in the treatment peptic ulcer disease (PUD). Eight degradants were found in the formulated drug under the stress conditions, (40°C/75% Relative Humidity (RH) for 6 mo) with Relative Retention Time’s (RRT’s) 0.26, 0.29, 0.32, 0.59, 0.88, 0.96, 1.12, and 1.33 by a LC-MS compatible method. A simple effective gradient preparative HPLC method was developed with the runtime of 20 min to isolate all the degradants. The degradants were stabilized and identified by UPLC-TOF MS. The method is capable and can be used to isolate further degradants. Supplemental materials are available for this article. Go to the publisher’s online edition of Journal of Liquid Chromatog. and Related Technologies to view the free supplemental file.

Journal of Liquid Chromatography & Related Technologies published new progress about 161796-78-7. 161796-78-7 belongs to imidazoles-derivatives, auxiliary class Membrane Transporter/Ion Channel,Proton Pump, name is Sodium (S)-6-methoxy-2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide, and the molecular formula is C11H21BF4N2O2, Application In Synthesis of 161796-78-7.

Referemce:
https://en.wikipedia.org/wiki/Imidazole,
Imidazole | C3H4N2 – PubChem

Talsi, Evgenii P. published the artcileIsoinversion Behavior in the Enantioselective Oxidations of Pyridylmethylthiobenzimidazoles to Chiral Proton Pump Inhibitors on Titanium Salalen Complexes, Formula: C17H18N3NaO3S, the publication is ACS Catalysis (2015), 5(8), 4673-4679, database is CAplus.

The oxidation of two pyridylmethylthiobenzimidazoles to proton pump inhibitors (S)-omeprazole and (R)-lansoprazole, and to their enantiomers, with H₂O₂ is achieved by using chiral titanium salalen complexes as catalysts. The latter ensure high enantioselectivities (up to 96% ee) and efficiencies (TN 200-300), with high sulfoxide yields (up to >96%). The oxidation enantioselectivities vary with temperature in a nonmonotonic manner, demonstrating isoinversion behavior. Maximum enantioselectivity is attained at 273···283 K, which temperature region may be recommended for preparative oxidations Kinetic peculiarities and the oxidation mechanism are discussed.

ACS Catalysis published new progress about 161796-78-7. 161796-78-7 belongs to imidazoles-derivatives, auxiliary class Membrane Transporter/Ion Channel,Proton Pump, name is Sodium (S)-6-methoxy-2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide, and the molecular formula is C8H11BO2, Formula: C17H18N3NaO3S.

Referemce:
https://en.wikipedia.org/wiki/Imidazole,
Imidazole | C3H4N2 – PubChem

Mahale, Rajendra D. published the artcileDavis Oxaziridine-Mediated Asymmetric Synthesis of Proton Pump Inhibitors Using DBU Salt of Prochiral Sulfide, Synthetic Route of 161796-78-7, the publication is Organic Process Research & Development (2010), 14(5), 1264-1268, database is CAplus.

A simple and clean asym. synthesis of proton pump inhibitors using inexpensive 10-camphorsulfonyl oxaziridine is described. The activation of prochiral sulfide is based on use of the DBU salt which is capable of enhancing the reactivity and enantioselectivity.

Organic Process Research & Development published new progress about 161796-78-7. 161796-78-7 belongs to imidazoles-derivatives, auxiliary class Membrane Transporter/Ion Channel,Proton Pump, name is Sodium (S)-6-methoxy-2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide, and the molecular formula is C17H18N3NaO3S, Synthetic Route of 161796-78-7.

Referemce:
https://en.wikipedia.org/wiki/Imidazole,
Imidazole | C3H4N2 – PubChem

Feng, Zi-Wei published the artcileStructural dependence on the property of chiral stationary phases derived from chitosan bis(arylcarbamate)-(amide)s, Application of Sodium (S)-6-methoxy-2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide, the publication is Carbohydrate Polymers (2017), 301-309, database is CAplus and MEDLINE.

The goal of present study was to study the structural dependence of chitosan derivatives on enantioseparation and mobile phase tolerance of the corresponding chiral packing materials for liquid chromatog. Hence, a series of chitosan bis(arylcarbamate)-(n-pentyl amide)s and the related chiral stationary phases (CSPs) were prepared from chitosans with different mol. weights Because of the H-bond formed via CH₃-π interaction, the CSP bearing Me substituent exhibited higher tolerance than the ones bearing dichloro substituents. The CSP derived from the chitosan bis(3,5-dichlorophenylcarbamate)-(n-pentyl amide) with a higher mol. weight possessed high tolerance to mobile phases, whereas the enantioseparation capability of this CSP was not as good as that of the one prepared from the chitosan derivative with a lower mol. weight Therefore, enantioseparation capability and mobile phase tolerance have to be counterbalanced in designing chiral selectors for the CSPs derived from chitosan bis(arylcarbamate)-(amide)s.

Carbohydrate Polymers published new progress about 161796-78-7. 161796-78-7 belongs to imidazoles-derivatives, auxiliary class Membrane Transporter/Ion Channel,Proton Pump, name is Sodium (S)-6-methoxy-2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide, and the molecular formula is C17H18N3NaO3S, Application of Sodium (S)-6-methoxy-2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide.

Referemce:
https://en.wikipedia.org/wiki/Imidazole,
Imidazole | C3H4N2 – PubChem

Narla, Divya published the artcileSimultaneous estimation of aceclofenac and esomeprazole sodium in bulk by RP-HPLC, COA of Formula: C17H18N3NaO3S, the publication is American Journal of PharmTech Research (2016), 6(2), 493-502, database is CAplus.

A simple, accurate, precise and specific RP-HPLC method has been developed for the simultaneous estimation of Aceclofenac and Esomeprazole Sodium in bulk. Chromatog. anal. was carried out on C18 column (250mm × 4.6mm, 5μm). Mobile phase used is a homogenous mixture of ACN: Methanol in the ratio of 50:50 volume/volume The detection was carried out at 285nm. The retention times were found to be 3.00 and 4.41 min for Aceclofenac and Esomeprazole Na resp. Both the drugs showed linearity in the range of 30 – 70mcg/mL. The correlation coefficient was found to be 0.99 and 0.992 for Aceclofenac and Esomeprazole Na resp. The developed method was validated as per ICH guidelines.

American Journal of PharmTech Research published new progress about 161796-78-7. 161796-78-7 belongs to imidazoles-derivatives, auxiliary class Membrane Transporter/Ion Channel,Proton Pump, name is Sodium (S)-6-methoxy-2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide, and the molecular formula is C17H18N3NaO3S, COA of Formula: C17H18N3NaO3S.

Referemce:
https://en.wikipedia.org/wiki/Imidazole,
Imidazole | C3H4N2 – PubChem

Zhi, Hui published the artcileOccurrence and spatiotemporal dynamics of pharmaceuticals in a temperate-region wastewater effluent-dominated stream: variable inputs and differential attenuation yield evolving complex exposure mixtures, Recommanded Product: Sodium (S)-6-methoxy-2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide, the publication is Environmental Science & Technology (2020), 54(20), 12967-12978, database is CAplus and MEDLINE.

Effluent-dominated streams are becoming increasingly common in temperate regions and generate complex pharmaceutical mixture exposure conditions that may impact aquatic organisms via drug-drug interactions. Here, we quantified spatiotemporal pharmaceutical exposure concentrations and composition mixture dynamics during baseflow conditions at four sites in a temperate-region effluent-dominated stream (upstream, at, and progressively downstream from effluent discharge). Samples were analyzed monthly for 1 yr for 109 pharmaceuticals/degradates using a comprehensive U.S. Geol. Survey anal. method and biweekly for 2 years focused on 14 most common pharmaceuticals/degradates. We observed a strong chem. gradient with pharmaceuticals only sporadically detected upstream from the effluent. Seventy-four individual pharmaceuticals/degradates were detected, spanning 5 orders of magnitude from 0.28 to 13 500 ng/L, with 38 compounds detected in >50% of samples. “Biweekly” compounds represented 77 ± 8% of the overall pharmaceutical concentration The antidiabetic drug metformin consistently had the highest concentration with limited instream attenuation. The antihistamine drug fexofenadine inputs were greater during warm- than cool-season conditions but also attenuated faster. Differential attenuation of individual pharmaceuticals (i.e., high = citalopram; low = metformin) contributed to complex mixture evolution along the stream reach. This research demonstrates that variable inputs over multiple years and differential instream attenuation of individual compounds generate evolving complex mixture exposure conditions for biota, with implications for interactive effects.

Environmental Science & Technology published new progress about 161796-78-7. 161796-78-7 belongs to imidazoles-derivatives, auxiliary class Membrane Transporter/Ion Channel,Proton Pump, name is Sodium (S)-6-methoxy-2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide, and the molecular formula is C7H6Cl2O, Recommanded Product: Sodium (S)-6-methoxy-2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide.

Referemce:
https://en.wikipedia.org/wiki/Imidazole,
Imidazole | C3H4N2 – PubChem